Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®
NCT00742183 · View on ClinicalTrials.gov ↗
Study Summary
The primary objective is to compare the incremental costs (direct and indirect) and benefits (healing outcomes, quality of life) of using foam silver dressing (Mepilex® Ag) to a Silver sulfadiazine 1% cream (Silvadene®) from the perspective of the health care provider. The secondary objectives are to investigate the safety, the tolerance and the performance on burn status including pain.
Conditions Studied
Interventions
- DEVICE Mepilex
- DEVICE Silvadene
Study Locations (10)
California
- LA County Hospital & USC Medical Center — Los Angeles
District of Columbia
- The Burn Center, Washington Hospital Center — Washington D.C.
Florida
- Shands Burn Center, University of Florida — Gainesville
Georgia
- Joseph Still Burn Center — Augusta
Iowa
- UI Burn Treatment center — Iowa City
New York
- Cornell Medical Center — New York
Oklahoma
- Paul Silverstein Burn center — Oklahoma City
Pennsylvania
- St Christopher's Hospital — Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-11 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742183
The ClinicalTrials.gov registry entry for NCT00742183 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molnlycke Health Care AB, which has 41 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Second Degree Burn appearing as the primary indexed condition, and to 2 interventions — of which Mepilex is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00742183 reports 10 study locations spanning 10 distinct geographic areas — top geographies include California, District of Columbia, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00742183 about?
NCT00742183 is a clinical study titled "Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®". The primary objective is to compare the incremental costs (direct and indirect) and benefits (healing outcomes, quality of life) of using foam silver dressing (Mepilex® Ag) to a Silver sulfadiazine 1% cream (Silvadene®) from the perspective of the health care provider. The secondary objectives are ...
What is the current status of trial NCT00742183?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2008-08. Estimated completion is 2009-11.
What conditions does trial NCT00742183 study?
This clinical trial studies the following conditions: Second Degree Burn. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00742183?
The interventions under investigation include: Mepilex (DEVICE), Silvadene (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00742183?
This trial is sponsored by Molnlycke Health Care AB, which has 41 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00742183 being conducted?
This trial has 10 study locations across California, District of Columbia, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.